Skip to main content
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2009 Aug;70(4):267–273. doi: 10.1016/j.curtheres.2009.08.003

Use of adjunctive mitomycin C in external dacryocystorhinostomy surgery compared with surgery alone in patients with nasolacrimal duct obstruction: A prospective, double-masked, randomized, controlled trial

Şeyhmus Ari 1,*, Ramazan Gun 2, Serdar Surmeli 1, Ahmet Engin Atay 3, Îhsan Çaca 4
PMCID: PMC3967366  PMID: 24683236

Abstract

Background: The most common cause for the failure of external dacryocystorhinostomy (DCR) surgery is the formation of granulation tissue at the osteotomy site or common canaliculus.

Objectives: The aims of this study were to assess the efficacy of intraoperative adjunctive mitomycin C (MMC) treatment in external DCR surgery and to compare this procedure with the standard DCR procedure alone in the long term (1 year).

Methods: In this prospective, double-masked, randomized, controlled trial, patients with primary acquired nasolacrimal duct obstruction were randomized (using a random number table) into 2 groups based on surgical procedure. In the MMC group, intraoperative adjunctive MMC 0.2 mg/mL was applied to the osteotomy site for 30 minutes. The control group underwent standard DCR procedure only. The results of the DCR surgeries were assessed using objective findings (eg, cessation of excessive tearing via nasolacrimal duct irrigation and the improvement in height of tear meniscus) and subjective symptoms (asking patients to describe the degree of tearing improvement). Both the patients and the researchers who were assessing the study outcomes were masked to treatment group.

Results: One hundred eyes of 100 Turkish patients were assessed and equally randomized to the MMC (27 women, 23 men; mean [SD] age, 47.0 [7.6] years) and control (26 women, 24 men; mean age, 46.6 [8.8] years) groups. The follow-up period was not significantly different between the MMC and the control groups (13.1 [1.1] vs 13.2 [1.4] months). Significantly more eyes in the MMC group than the control group remained symptom-free throughout the 1-year follow-up period (45/50 [90%] vs 33/50 [66%]; P=0.005). Significantly more patients in the control group than the MMC group had an improvement in symptoms at the 1-year follow-up (8/50 [16%] vs 2/50 [4%] eyes; P=0.005). Based on the patency of the drainage system, the success rate was significantly greater in the MMC group than the control group (48/50 [96%] vs 42/50 [84%]; P=0.005). Based on nasolacrimal duct irrigation, significantly fewer patients in the MMC group than the control group had an enclosed naso-lacrimal duct (2/50 [4%] vs 8/50 [16%]). No adverse effects (eg, abnormal nasal bleeding, mucosal necrosis, infection) or any other surgical adverse events were observed.

Conclusions: In the management of these patients with primary acquired nasolacrimal duct obstruction, adjunctive intraoperative MMC application with standard DCR surgery had a significantly higher success rate than did standard DCR surgery alone. Further large, double-masked, randomized studies are needed to confirm these findings.

Key words: dacryocystorhinostomy, nasolacrimal duct obstruction, mitomycin C

Full Text

The Full Text of this article is available as a PDF (611.9 KB).

References

  • 1.Walland MJ, Rose GE. Factors affecting the success rate of open lacrimal surgery. Br J Ophthalmol. 1994;78:888–891. doi: 10.1136/bjo.78.12.888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Keerl R, Weber R. Dacryocystorhinostomy—state of the art, indications, results [in German] Laryngorhinootologie. 2004;83:40–50. doi: 10.1055/s-2004-814110. [DOI] [PubMed] [Google Scholar]
  • 3.Roozitalab MH, Amirahmadi M, Namazi MR. Results of the application of intraoperative mitomycin C in dacryocystorhinostomy. Eur J Ophthalmol. 2004;14:461–463. doi: 10.1177/112067210401400602. [DOI] [PubMed] [Google Scholar]
  • 4.Liao SL, Kao CS, Tseng JH. Results of intraoperative mitomycin C application in dacryocystorhinostomy. Br J Ophthalmol. 2000;84:903–906. doi: 10.1136/bjo.84.8.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ibrahim HA, Batterbury M, Banhegyi G, McGalliard J. Endonasal laser dacryocystorhinostomy and external dacryocystorhinostomy outcome profile in a general ophthalmic service unit: A comparative retrospective study. Ophthalmic Surg Lasers. 2001;32:220–227. [PubMed] [Google Scholar]
  • 6.Yildirim C, Yaylali V, Esme A, Ozden S. Long-term results of adjunctive use of mitomycin C in external dacryocystorhinostomy. Int Ophthalmol. 2007;27:31–35. doi: 10.1007/s10792-007-9057-6. [DOI] [PubMed] [Google Scholar]
  • 7.Cokkeser Y, Evereklioglu C, Er H. Comparative external versus endoscopic dacryocystorhinostomy: Results in 115 patients (130 eyes) Otolaryngol Head Neck Surg. 2000;123:488–491. doi: 10.1067/mhn.2000.105470. [DOI] [PubMed] [Google Scholar]
  • 8.Demarco R, Strose A, Araújo M. Endoscopic revision of external dacryocystorhinostomy. Otolaryngol Head Neck Surg. 2007;137:497–499. doi: 10.1016/j.otohns.2007.03.023. [DOI] [PubMed] [Google Scholar]
  • 9.Baldeschi L, Nardi M, Hintschich CR, Koornneef L. Anterior suspended flaps: A modified approach for external dacryocystorhinostomy. Br J Ophthalmol. 1998;82:790–792. doi: 10.1136/bjo.82.7.790. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kao SC, Liao CL, Tseng JH. Dacryocystorhinostomy with intraoperative mitomycin C. Ophthalmology. 1997;104:86–91. doi: 10.1016/s0161-6420(97)30357-1. [DOI] [PubMed] [Google Scholar]
  • 11.Kashkouli MB, Parvaresh MM, Mirzajani H. Intraoperative mitomycin C use during filtration surgery and lacrimal drainage system obstruction. Am J Ophthalmol. 2009;147:453–457. doi: 10.1016/j.ajo.2008.08.037. [DOI] [PubMed] [Google Scholar]
  • 12.Deka A, Bhattacharjee K, Bhuyan SK. Effect of mitomycin C on ostium in dacryocysto-rhinostomy. Clin Experiment Ophthalmol. 2006;34:557–561. doi: 10.1111/j.1442-9071.2006.01265.x. [DOI] [PubMed] [Google Scholar]
  • 13.Yeatts RP, Neves RB. Use of mitomycin C in repeat dacryocystorhinostomy. Ophthal Plast Reconstr Surg. 1999;15:19–22. doi: 10.1097/00002341-199901000-00005. [DOI] [PubMed] [Google Scholar]
  • 14.Ugurbas SH, Zilelioglu G, Sargon MF. Histopathologic effects of mitomycin-C on endoscopic transnasal dacryocystorhinostomy. Ophthalmic Surg Lasers. 1997;28:300–304. [PubMed] [Google Scholar]
  • 15.You YA, Fang CT. Intraoperative mitomycin C in dacryocystorhinostomy. Ophthal Plast Reconstr Surg. 2001;17:115–119. doi: 10.1097/00002341-200103000-00007. [DOI] [PubMed] [Google Scholar]
  • 16.Mearza AA, Aslanides IM. Uses and complications of mitomycin C in ophthalmology. Expert Opin Drug Saf. 2007;6:27–32. doi: 10.1517/14740338.6.1.27. [DOI] [PubMed] [Google Scholar]
  • 17.Hyung SM, Jung MS. Management of hypotony after trabeculectomy with mitomycin C. Korean J Ophthalmol. 2003;17:114–121. doi: 10.3341/kjo.2003.17.2.114. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES